Metabolic syndrome is common in psoriatic arthritis and is a known risk factor for worse symptoms and poor treatment outcomes. This study sought to explore the syndrome's role in a more precisely ...

Deucravacitinib met its primary endpoint of more than 20% improvement in ACR20 response among patients with psoriatic ...

Arthritis awareness emphasizes early detection of arthritis, a condition affecting joints, bones, and muscles. Recognizing ...

There are, however, treatments for psoriasis and psoriatic arthritis that do not work in rheumatoid arthritis. Psoriasis is more commonly associated with psoriatic arthritis, but it’s also ...

Steqeyma is now supplied as a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection, allowing for weight-based dosing for pediatric patients under 60kg.

ALTB-268 demonstrated therapeutic potential in murine models of colitis and GvHD, supporting its role as an immune checkpoint enhancer in T cell-mediated ...

The following six biosimilars were given a positive opinion at the June meeting: treatments for treatment of age-related macular degeneration and visual impairment: Mynzepli (aflibercept), and its ...

The debate over the Biosimilar Red Tape Elimination Act raises critical concerns about FDA standards, physician trust, and ...